Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 1/20 | 0.37 |
| ▸ | RBBP4 | Q09028 | 1/20 | 0.37 |
| ▸ | SUZ12 | Q15022 | 1/20 | 0.37 |
| ▸ | EZH2 | Q15910 | 1/20 | 0.37 |
| ▸ | AEBP2 | Q6ZN18 | 1/20 | 0.37 |
| ▸ | ROCK1 | Q13464 | 4/20 | 0.36 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.36 |
| ▸ | CNR2 | P34972 | 4/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | SLC5A1 | P13866 | 1/20 | 0.33 |
| ▸ | SLC16A3 | O15427 | 1/20 | 0.33 |
| ▸ | SLC16A1 | P53985 | 1/20 | 0.33 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.32 |
| ▸ | SIRT3 | Q9NTG7 | 1/20 | 0.32 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.32 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.32 |
| ▸ | PIK3R2 | O00459 | 1/20 | 0.32 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.32 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL332704 | 0.82 | PDE8B (0.39) | ROCK1 | |
| SCHEMBL13008112 | 0.77 | DHODH (0.34) | — | |
| SCHEMBL331823 | 0.75 | — | — | |
| SCHEMBL331703 | 0.75 | ALDH1A1 (0.34) | — | |
| SCHEMBL331639 | 0.72 | — | — | |
| SCHEMBL15882099 | 0.70 | ROCK1 (0.50) | ROCK1ROCK2CNR2CNR1 | |
| SCHEMBL31429384 | 0.70 | ROCK1 (0.50) | ROCK1ROCK2CNR2CNR1 | |
| SCHEMBL332811 | 0.70 | — | — | |
| SCHEMBL332452 | 0.70 | CACNA1G (0.32) | — | |
| SCHEMBL331706 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| US-8097621-B2 | Pyrazolo[4,3-d]pyrimidines as phosphodiesterase inhibitors | PFIZER INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| EP-1689751-B1 | 5,7-DIAMINOPYRAZOLO[4,3-D]PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LTD (GB) | 2010-10-20 | — | — | EP | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-20090247539-A1 | Novel Pharmaceuticals | PFIZER INC | 2009-10-01 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-7572799-B2 | Pyrazolo[4,3-d]pyrimidines as Phosphodiesterase Inhibitors | PFIZER INC (US) | 2009-08-11 | — | — | US | disclosed |
| US-20050245544-A1 | Novel pharmaceuticals | AMPLIFIED PROTEOMICS INC. | 2005-11-03 | — | — | US | disclosed |
| WO-2005049616-A1 | 5,7-DIAMINOPYRAZOLO [4,3-d] PYRIMIDINES WITH PDE-5 INHIBITING ACTIVITY | PFIZER LIMITED (GB) | 2005-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050245544-A1 | Novel pharmaceuticals | ABCB11, PCSK9, SLC10A1 | EED 4110/4885RBBP4 4821/4885SUZ12 2734/4885 |
| US-20090247539-A1 | Novel Pharmaceuticals | ABCB11, PCSK9, SLC10A1 | EED 4110/4885RBBP4 4821/4885SUZ12 2734/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.